Scribe Therapeutics is the latest biotech to prepare a public listing, as the company looks to propel its lipid-lowering medicines through clinical trials. While the Bay Area biotech has yet to set ...

A month after Genentech confirmed the restructuring of its early development group, the Roche subsidiary has now disclosed ...

Novartis is pushing deeper into antibody-drug conjugate (ADC) development, paying $1.1 billion upfront to buy Myricx Bio for a pipeline based on a novel payload. Switzerland’s Novartis largely stayed ...

The Fosun subsidiary is paying the upfront fee, committing up to 1.12 billion yuan ($166 million) in milestones and agreeing ...

Despite decades of scientific progress and billions of dollars invested in oncology research, metastatic cancer remains overwhelmingly incurable. While many therapies can delay disease progression and ...

Roche’s investigational KRAS G12C inhibitor has beaten Amgen’s Lumakras and Bristol Myers Squibb’s Krazati in a phase 3 trial ...

Insilico Medicine has signed a deal worth up to $600 million with Takeda to collaborate on asset discovery across the Japan Big Pharma's therapeutic areas of interest.  | Insilico Medicine has signed ...

Merck & Co. has nixed the phase 2 study of a potential Alzheimer’s disease medicine after the drug underwhelmed in an interim analysis, marking another blow for the pharma’s struggling partner ...

Vijay Kumar, the acting head of the FDA office that oversees new gene therapies, is stepping down from his role after a year in the job. As Kumar’s tenure atop the Office of Therapeutic Products (OTP) ...

QuantumCell has licensed AlzeCure Pharma’s Alzheimer’s disease platform and lead asset for $12 million upfront in a heavily back-loaded deal that bags a potentially symptom-relieving drug candidate on ...

Ipsen is on a roll this week, scooping up its second biotech in three days in order to firm up its pipeline with promising clinical-stage candidates. This morning’s deal sees the French biopharma ...